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   The clinical effectiveness， safety and usefullness of ’the alpha－adrener，gic blocker， Ea－
0643 tablet， for the treatment of the neurogenic blaclder were evaluated by the double blind
test method． A total of 61 patients was treated． Five of them were excluded ot dropped
out． Eighteen patients （group－A） received a 1．Orng tablet of Ea－0643， 20 patients （group－B）
received a O．5 mg tablet of Ea－0643 and 17 patients （group－C） received a placebo tablet．
Each tablet was administered orally three ’times a day ’for two weel〈s． rl”here wTas no
significant difference in the backgroupd factors between the three groups．
   The rate of effectiveness ’for ．subjective symptoms was 22．2％ in group－A， 30．09zof in group－
B and 35．3％ in’ group－C． There NsTas no sigpificant difference between the three groups．
   The rate of effectivenes＄ ’for residual urine，．．judged by clecrease in vaiue of” residural
urine rate after treatment of less than 25％， was 55．6％ in group－A， 35．0％ in group－B and
17．6％ in group－C． ［1］he rate of effectiveness in group－A was significantly hi．crher than that in
group－C． The mean va1ue of’net decreased residural urine rate after’ treatment in bcrroup－A
was cignificantly higher than that in group－C．
   D．ecrease of maximal urethral pr．essure by more than 5 cm H20 was seen in 44．4％ of
group－A， 35．0％ of group－B and 41．2％o of group－C． ’1’hcre was no siffbnificatit difference be－
tween the three g’roups．
   The rate of improvement for flow rate was 66．7％ in group－A， 46．2％ in group B and 36．4
％o in group－C． There was no sig’nificant difference between the three g．i’oups， but the mean
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value of net increased averabcre flow rate after treatment in group－A was significantly higher
thhn that in group－C．
  The rate ofeffectiveness for overall fun．ction testfi was 55．6％ in． group A， 25．0％ in group－
B and 23．5％ in’№秩fotiP－C． There was no significant difference between the・three groups．
  The clinical effe6tive rate including excellent and moderate．was 38．9％ in group－A， 25．0
％ in group－B and 23．5％ in group－C． There was ’no significant difference between the three
groups．
  Side effects were observed in 2 patients in group－A， 3 patients in group－B and one pqtient
in group－C． Abnormal values for clinical lavoratory te．sts were seen in 3 patients in group－
B． The incidence of adverse reactions． in group－B was significantly higher than that in group－
C． There was no significant difference between groups A and C．
  The．rate of clinical usefullness’was 38．9％．in group－A， 25．0％ in group－B， and 23．5％ in
group－G． There was no signiflcant diff6rence between． the three groups。
  Based on these results， it was considered that administration of Ea－0643 3．0．mg per day
would be effective for the treatment of neurogenic bladders．
























































                村山・ほか：
 2）試験薬剤と投与方法
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神経因性膀胱・α一遮断剤
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間able 2．患者背景因子
自覚症
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①副作用なし   ②軽度副作用
③中等度副作用   ④高度副作用
5）有用性判定
総合改善度に安全性を加味してつぎのように判定し
      中枢性
      脊髄性
基礎疾患
     末梢性
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          村山・ほか：神経因性膀胱・α一遮断剤
Tablc 4’残尿率改善度              Table 8．、総合改善度
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Table 5．最高尿道内圧改善度 Table 9．安全度判定
 判定著明       改善  不 変薬剤  改善 計  検定
 副作用    なし 軽度 中等度
薬剤
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201±97．0 220±134．6               NS
   l9±t12．7（17）
残尿率
 （e／a）
46±17．2     29±20．9糊。  42±20．0     29±18．7林   43±22．i     38±27．7
                                           A一ひ




65±26．6 59±32．8 70±25．6 67±26，2 64±28．4
一一 U．7±23．60（18） 一2．i±i8．29（20）





12，1±4．5316．8±7，el 10．4±4．8411．4＝ヒ4．71  11．5±10．21  10」±5．43





5．4±2．21 8．2±3，24＊ 3．9±1．24 4．7±2．03
2．9±3．52（9） O．8±2．29（IO）
3．0±1．82 3．0±1．63






薬 剤 A B c




ヘマトクリット ％36．4±5．44（18）36，7±4．94 37．［±5．20（19）36．8±4．92 40．4±4．43（19）40．2±4．60
GOT u．
GPT u．
A卜P   KAU
総コレステロール
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   （担当医が異常と判断したもの）
185Z
              検 査 値薬剤番号 性年齢検査項目                    担当医コメント             投与前投与後 再検査（日数）
2－7（B）
    GOT  72→136→59（5日後）
￥ 68
    GPT  88→190→54（5艮後）
関連性不明
5－3（B） ♀ 55 GPT l2？38→27（i媚後）関連性強い
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